Achmea Investment Management B.V. Raises Position in Illumina, Inc. (NASDAQ:ILMN)

Achmea Investment Management B.V. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 73.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 61,094 shares of the life sciences company's stock after acquiring an additional 25,873 shares during the quarter. Achmea Investment Management B.V.'s holdings in Illumina were worth $4,847,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ILMN. IFP Advisors Inc increased its holdings in shares of Illumina by 19.1% in the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock worth $82,000 after acquiring an additional 99 shares in the last quarter. Mn Services Vermogensbeheer B.V. grew its holdings in shares of Illumina by 1.6% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 61,900 shares of the life sciences company's stock worth $8,272,000 after buying an additional 1,000 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Illumina during the fourth quarter worth about $901,000. Proficio Capital Partners LLC bought a new position in shares of Illumina during the fourth quarter worth about $10,875,000. Finally, QRG Capital Management Inc. grew its holdings in shares of Illumina by 35.1% during the fourth quarter. QRG Capital Management Inc. now owns 11,365 shares of the life sciences company's stock worth $1,519,000 after buying an additional 2,954 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

Illumina stock traded up $0.63 during trading on Friday, hitting $94.79. The stock had a trading volume of 3,837,289 shares, compared to its average volume of 2,142,698. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The stock's 50 day moving average is $82.69 and its two-hundred day moving average is $98.98. The stock has a market cap of $15.01 billion, a price-to-earnings ratio of -15.62, a price-to-earnings-growth ratio of 1.86 and a beta of 1.32.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.98 earnings per share. As a group, analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Buying and Selling

In related news, CFO Ankur Dhingra acquired 6,100 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 2.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Morgan Stanley decreased their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Piper Sandler decreased their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a report on Thursday, May 15th. Robert W. Baird reduced their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Stephens reissued an "overweight" rating and set a $105.00 price target on shares of Illumina in a research report on Tuesday, May 20th. Finally, Royal Bank Of Canada reduced their price target on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $127.39.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.